Innate Pharma (IPHYF) Stock Price, News & Analysis

Company Overview

Innate Pharma is a clinical‐stage biotechnology company specializing in the discovery and development of novel immunotherapies that harness the body’s innate immune system to fight cancer. The company focuses on monoclonal antibodies that target key receptors and ligands involved in immune regulation, aiming to restore natural anti‐tumor responses. Its research platform integrates proprietary antibody engineering and screening technologies to identify therapeutic candidates with optimized efficacy and safety profiles.

The company’s lead programs include monalizumab, an anti‐NKG2A checkpoint inhibitor in collaboration with AstraZeneca, and lacutamab, an anti‐KIR3DL2 antibody for T‐cell lymphomas. In addition to these advanced assets, Innate Pharma’s pipeline features earlier‐stage candidates such as IPH5201, targeting CD39, and IPH4102, directed against KIR3DL2 in rare hematologic malignancies. Through strategic partnerships with major pharmaceutical firms, the company leverages external expertise and resources to accelerate clinical development and global commercial potential.

Founded in 1999 and headquartered in Marseille, France, Innate Pharma is led by Chief Executive Officer Mondher Mahjoubi and a team of seasoned executives with deep experience in oncology drug development. The company maintains research facilities in Europe and the United States, supporting a global footprint that extends across North America, Europe, and Asia. Since its initial public listing on Euronext Paris, Innate Pharma has built a reputation for pioneering innate immunology and advancing novel therapeutic modalities to address unmet needs in oncology.

Key Stats

• Today's Range: $1.31 to $1.31
• 50-Day Range: $1.31 to $1.95
• 52-Week Range: $1.31 to $1.95
• Volume: N/A
• Average Volume: 38 shs
• Market Capitalization: $109.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IPHYF Stock Analysis - Frequently Asked Questions

How have IPHYF shares performed this year?

Innate Pharma's stock was trading at $2.90 at the beginning of the year. Since then, IPHYF stock has decreased by 54.8% and is now trading at $1.31.

How do I buy shares of Innate Pharma?

Shares of IPHYF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/18/2025
• Next Earnings (Estimated): 9/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:IPHYF
• Previous Symbol: NASDAQ:IPHYF
• CIK: 1598599
• Web: www.innate-pharma.com
• Phone: (343) 030-3030
• Fax: 33-04-30-30-30-00
• Employees: 179
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.60
• Quick Ratio: 2.60

Sales & Book Value

• Annual Sales: $21.77 million
• Price / Sales: 5.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.11 per share
• Price / Book: 11.91

Miscellaneous

• Outstanding Shares: 83,830,000
• Free Float: 57,097,000
• Market Cap: $109.82 million
• Optionable: Not Optionable
• Beta: 0.50